These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28755023)

  • 1. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
    Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
    Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.
    Helfenstein S; Riesterer O; Meier UR; Papachristofilou A; Kasenda B; Pless M; Rothschild SI
    Radiat Oncol; 2019 Feb; 14(1):32. PubMed ID: 30744643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
    Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
    Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
    J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
    Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
    Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
    Rades D; Strojan P; Seidl D; Janssen S; Bajrovic A; Kazic N; Hakim SG; Wollenberg B; Schild SE
    J Craniomaxillofac Surg; 2016 Sep; 44(9):1436-40. PubMed ID: 27499514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers.
    Rades D; Seidl D; Janssen S; Bajrovic A; Karner K; Strojan P; Schild SE
    BMC Cancer; 2016 Jul; 16():437. PubMed ID: 27391309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
    Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
    Chang CL; Yuan KS; Wu SY
    Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.
    Maguire PD; Papagikos M; Hamann S; Neal C; Meyerson M; Hayes N; Ungaro P; Kotz K; Couch M; Pollock H; Tepper J
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1081-8. PubMed ID: 20378262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
    Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
    Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
    Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
    Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
    Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
    Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
    Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiotherapy with high-dose cisplatin compared with weekly cisplatin for locally advanced head and neck squamous cell carcinoma.
    Hughes RT; Porosnicu M; Levine BJ; Lycan TW; Shenker RF; Frizzell BA; Greven KM
    J Med Imaging Radiat Oncol; 2021 Oct; 65(6):796-805. PubMed ID: 34309212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
    Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
    J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.